Investigational Drug Information for CCX168
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug CCX168?
CCX168 is an investigational drug.
There have been 7 clinical trials for CCX168.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 15th 2017.
The most common disease conditions in clinical trials are Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, and Atypical Hemolytic Uremic Syndrome. The leading clinical trial sponsors are ChemoCentryx, Mario Negri Institute for Pharmacological Research, and Medpace, Inc.
There are seven US patents protecting this investigational drug and one hundred and seventy-four international patents.
Summary for CCX168
| US Patents | 7 |
| International Patents | 174 |
| US Patent Applications | 85 |
| WIPO Patent Applications | 46 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 3 (2017-03-15) |
| Vendors | 21 |
Recent Clinical Trials for CCX168
| Title | Sponsor | Phase |
|---|---|---|
| Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA) | ChemoCentryx | Phase 2 |
| Controlled Trial Evaluating Avacopan in C3 Glomerulopathy | Medpace, Inc. | Phase 2 |
| Controlled Trial Evaluating Avacopan in C3 Glomerulopathy | ChemoCentryx | Phase 2 |
Clinical Trial Summary for CCX168
Top disease conditions for CCX168
Top clinical trial sponsors for CCX168
US Patents for CCX168
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CCX168 | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| CCX168 | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| CCX168 | See Plans and Pricing | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | See Plans and Pricing |
| CCX168 | See Plans and Pricing | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| CCX168 | See Plans and Pricing | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CCX168
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CCX168 | Argentina | AR077162 | 2028-12-22 | See Plans and Pricing |
| CCX168 | Australia | AU2009330194 | 2028-12-22 | See Plans and Pricing |
| CCX168 | Brazil | BR112012033075 | 2028-12-22 | See Plans and Pricing |
| CCX168 | Brazil | BRPI0923384 | 2028-12-22 | See Plans and Pricing |
| CCX168 | Canada | CA2747522 | 2028-12-22 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
